FOLH1 and metastatic malignant neoplasm in the lymph nodes: Comparing activity of [18F]-PSMA avid lymph node metastases (n = 75) with axillary lymph nodes of vaccinated patients, we observed a significantly higher [18F]-PSMA uptake of lymph node metastases, with a median SUVmax of 13.3 (range, 6.8–21.3), p < 0.001, Figure 3.